Adaptive Biotechnologies Dirección
Dirección controles de criterios 2/4
El CEO de Adaptive Biotechnologies' es Chad Robins , nombrado en Sep 2009, tiene una permanencia de 14.58 años. compensación anual total es $8.85M, compuesta por 7.4% salario y 92.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.78% de las acciones de la empresa, por valor de $6.73M. La antigüedad media del equipo directivo y de la junta directiva es de 5.1 años y 8.3 años, respectivamente.
Información clave
Chad Robins
Chief Executive Officer (CEO)
US$8.9m
Compensación total
| Porcentaje del salario del CEO | 7.4% |
| Permanencia del CEO | 14.7yrs |
| Participación del CEO | 1.2% |
| Permanencia media de la dirección | 5.2yrs |
| Promedio de permanencia en la Junta Directiva | 8.3yrs |
Actualizaciones recientes de la dirección
Recent updates
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03
Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Our First Assessment On Adaptive Biotechnologies
Dec 16Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Sep 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$423k | -US$46m |
Compensación vs. Mercado: La compensación total de Chad($USD8.85M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Chad ha aumentado mientras la empresa no es rentable.
CEO
Chad Robins (48 yo)
14.7yrs
Permanencia
US$8,904,267
Compensación
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 14.7yrs | US$8.90m | 1.23% $ 5.6m | |
| President & COO | 6.3yrs | US$2.97m | 0.32% $ 1.5m | |
| Co-Founder & Chief Scientific Officer | 14.7yrs | US$8.61m | 0.69% $ 3.2m | |
| Chief Commercial Officer of Immune Medicine | 6.3yrs | US$2.88m | 0.22% $ 1.0m | |
| Founder | no data | sin datos | sin datos | |
| VP, CFO & Principal Accounting Officer | 2.6yrs | US$1.66m | 0.084% $ 383.5k | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Senior VP | 5.2yrs | sin datos | 0.11% $ 517.2k | |
| Chief People Officer | 5.1yrs | sin datos | 0.17% $ 796.9k | |
| Chief Commercial Officer of MRD | 3.8yrs | sin datos | 0.17% $ 772.2k | |
| Senior Vice President of MRD BioPharma | less than a year | sin datos | sin datos |
5.2yrs
Permanencia media
48.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ADPT es experimentado (5.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 14.7yrs | US$8.90m | 1.23% $ 5.6m | |
| Lead Independent Director | 10.4yrs | US$355.00k | 0.094% $ 429.1k | |
| Member of Corporate Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.2yrs | US$330.00k | 0.035% $ 161.6k | |
| Independent Director | 11.3yrs | US$325.00k | 0.052% $ 236.3k | |
| Independent General Partner | 6.3yrs | US$310.00k | 0.037% $ 168.8k | |
| Member of Corporate Advisory Board | no data | sin datos | sin datos | |
| Member of Corporate Advisory Board | no data | sin datos | sin datos | |
| Member of Corporate Advisory Board | no data | sin datos | sin datos | |
| Member of Corporate Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.2yrs | US$310.00k | 0.038% $ 174.5k |
8.3yrs
Permanencia media
57.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ADPT se considera experimentada (8.3 años de antigüedad promedio).